Prof. Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the phase III results from the RESONATE study in 391 patients with relapsed refractory chronic lymphoid leukemia (CLL). Prof Hillmen outlines the PFS and OS results that showed the significant benefits of ibrutinib over ofatumumab. He comments on single vs. combination therapy with ibrutinib in CLL.